Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe Press release
Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024 Press release
Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth Press release
